In this article, we will look at the 10 Best Growth Stocks to Buy With Huge Upside Potential.
On July 8, Tom Lee, head of research at Fundstrat, joined CNBC to discuss how the US tariffs might impact the market, economy, and inflation. The market seems to have digested the tariff episodes, and the current rally shows that the market doesn’t think that tariffs are going to cause turmoil. Lee noted that we now have enough data to infer that tariffs are not necessarily hurting the consumer’s wallet or job growth yet. However, we still need to wait and see its effect on inflation. Lee believes that the next inflation reports are important because if the tariff impact does not show up in upticking the core and consumer inflation, it will be good for the stock market.
Lee noted that the market is trying to keep a balance between the harsh statements coming from the White House to put pressure on closing deals and the practicality of these statements. Moreover, as the data shows that the policy is not impacting the economy as of yet, the White House is likely to continue with its tariff agenda, while ensuring that it does not derail the economy. Lee highlighted that while there are chances that volatility might increase, investors should keep the April 2nd scenario in mind, where the market rebounded in a V-shaped rally.
With that, let’s take a look at the 10 best growth stocks to buy with huge upside potential.
A graph monitoring stocks in a modern financial institution.
Our Methodology
To compile the list of 10 best growth stocks to buy with a huge upside potential, we used the Finviz stock screener and CNN as our sources. Using the screener, we aggregated a list of growth stocks with more than 40% upside potential. Next, we cross-checked the upside potential from CNN and ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s Q1 2025 database. Please note that the data was recorded on July 7, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best Growth Stocks to Buy With Huge Upside Potential
10. Genmab A/S (NASDAQ:GMAB)
Analyst Upside Potential: 50.64%
Number of Hedge Fund Holders: 20
Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study tested Epcoritamab, which is a bispecific antibody, in combination with R-ICE chemotherapy.
The study was focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma who could undergo autologous stem cell transplantation. The results revealed that the combination therapy achieved an overall response rate of 87%. Moreover, 65% of patients had a complete response where no signs of cancer remained. On the other hand, 23% had a partial response.
The treatment was regarded as generally well-tolerated, and the most common side effects were low white blood cells, anemia, and low platelets. These results are promising for high-risk patients who need new options. The combination may help more patients reach a stem cell transplant, which can be curative. However, this therapy is still investigational and not yet approved for this use.
Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that develops antibody-based therapies for cancer and other diseases.
9. Cellebrite DI Ltd. (NASDAQ:CLBT)
Analyst Upside Potential: 53.87%
Number of Hedge Fund Holders: 30
Cellebrite DI Ltd. (NASDAQ:CLBT) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 25, Cellebrite DI Ltd. (NASDAQ:CLBT) announced expanding its partnership with the National Center for Missing and Exploited Children (NCMEC) to help speed up investigations involving crimes against children.
A key part of this collaboration is the integration of NCMEC’s CyberTipline hash value list into Cellebrite DI Ltd. (NASDAQ:CLBT)’s main forensic software called the Cellebrite Inseyets. This list contains digital fingerprints, called hashes, of about 10 million files that have been confirmed as child sexual abuse material.
The integration allows investigators to instantly match files found on suspects’ devices to known CSAM. The integration is part of Cellebrite DI Ltd. (NASDAQ:CLBT)’s “Operation Find Them All” initiative. The program was launched in early 2024 and helps agencies use technology to rescue children and catch offenders.
Cellebrite DI Ltd. (NASDAQ:CLBT) is a software company that provides a Digital Intelligence platform designed to support legally sanctioned digital investigations.
8. Aurora Innovation, Inc. (NASDAQ:AUR)
Analyst Upside Potential: 124.30%
Number of Hedge Fund Holders: 33
Aurora Innovation, Inc. (NASDAQ:AUR) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On May 15, George Gianarikas from Canaccord Genuity maintained a Buy rating on Aurora Innovation, Inc. (NASDAQ:AUR) with a price target of $15.
The analyst highlighted Aurora Innovation, Inc. (NASDAQ:AUR)’s advanced approach to Level 4 autonomy through its hybrid system called the Aurora Driver. The system integrates AI, machine learning, and a sophisticated sensor suite. Gianarikas noted that the system is supported by over 1,450 issued and pending patents, showcasing strong intellectual property and innovation.
The analyst also likes the company’s leadership, which includes co-founder Sterling Anderson, who has a notable background from Tesla’s Autopilot program and MIT robotics. Gianarikas sees this as a significant asset that enhances his confidence in Aurora Innovation, Inc. (NASDAQ:AUR)’s strategic direction.
Aurora Innovation, Inc. (NASDAQ:AUR) develops the Aurora Driver, an advanced self-driving technology platform that can be integrated into various vehicle types, including passenger cars, light commercial vehicles, and Class 8 trucks.
7. QXO, Inc. (NYSE:QXO)
Analyst Upside Potential: 43.39%
Number of Hedge Fund Holders: 36
QXO, Inc. (NYSE:QXO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 18, QXO, Inc. (NYSE:QXO) made an offer to acquire GMS Inc. (NYSE:GMS) for about $5 billion in cash. This was part of the company’s strategy to become a $50 billion building product distributor.
However, on June 30 GMS Inc. (NYSE:GMS) announced entering into an agreement with The Home Depot to be acquired by SRS Distribution for approximately $5.5 billion. Thereby kicking QXO, Inc. (NYSE:QXO) out of the bidding war. Home Depot will commence a cash tender offer to purchase all outstanding shares of GMS common stock for $110 per share. This will result in a deal of $4.3 billion for Home Depot or $5.5 billion including debt. The company outbid QXO, Inc.’s (NYSE:QXO) proposal of $95.20 per-share offer.
QXO, Inc. (NYSE:QXO) delivers technology solutions mainly to manufacturing, distribution, and service sector clients.
6. Molina Healthcare, Inc. (NYSE:MOH)
Analyst Upside Potential: 105.23%
Number of Hedge Fund Holders: 38
Molina Healthcare, Inc. (NYSE:MOH) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 7, Molina Healthcare, Inc. (NYSE:MOH) announced its preliminary financial results for the fiscal second quarter of 2025 along with an update to its full-year EPS guidance.
As per the latest update, Molina Healthcare, Inc. (NYSE:MOH) expects second quarter earnings around $5.50 per share, reflecting a modest decline from the previous expectation. The decline is due to the medical cost pressure across all three lines of business. Management noted that this pressure is expected to stay for the rest of the year.
As a result, the company also adjusted its full-year 2025 earnings outlook. Molina Healthcare, Inc. (NYSE:MOH) now expects to earn between $21.50 and $22.50 per share for the year. This range is at the low end of its long-term targets. The company’s CEO, Joseph Zubretsky, explained the situation, noting the short-term drop in earnings was due to a gap between how fast medical costs are rising and how quickly premium rates are adjusted. He called this a temporary issue and noted that the company’s long-term outlook is unchanged, even with possible effects from new budget laws.
Molina Healthcare, Inc. (NYSE:MOH) is a managed care company that provides health insurance and healthcare services mainly through government programs like Medicaid and Medicare.
5. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)
Analyst Upside Potential: 58.05%
Number of Hedge Fund Holders: 41
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 2, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) announced that it has been selected by Versicherungskammer Group, a major insurance company, to handle its investment operations.
Versicherungskammer Group noted that it conducted a thorough review of its operating model starting in 2024. The company needed to adapt to market changes and demographic shifts. Therefore, after a structured selection process, it decided to select Clearwater Analytics Holdings, Inc. (NYSE:CWAN)’s modern, cloud-based platform.
The platform offers real-time, advanced data analytics, which will help Versicherungskammer make better investment decisions and improve performance.
Clearwater Analytics Holdings, Inc. provides a cloud-based platform that helps institutional investors manage their investments across public and private markets. Their system integrates portfolio management, accounting, risk analytics, and reporting into one unified solution.
4. Remitly Global, Inc. (NASDAQ:RELY)
Analyst Upside Potential: 45.16%
Number of Hedge Fund Holders: 46
Remitly Global, Inc. (NASDAQ:RELY) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 17, Goldman Sachs analyst Will Nance reiterated a Buy rating on Remitly Global, Inc. (NASDAQ:RELY) without disclosing any price target.
The reiterated bullish sentiment comes after the company reported its fiscal first quarter results for 2025 and raised its full-year outlook. Remitly Global, Inc. (NASDAQ:RELY) grew its revenue by 34% year-over-year, reaching $361.6 million. This was driven by a 29% growth in active customers and improved send volume, which grew 41% during the same time.
Management now expects full-year revenue for 2025 to be in the range of $1.574 billion to $1.587 billion against the previous outlook of $1.565 billion to $1.580 billion. The outlook for adjusted EBITDA also improved from $180 million to $200 million to a range of $195 million to $210 million.
Remitly Global, Inc. (NASDAQ:RELY) is a technology company that provides a digital platform for fast, reliable, and transparent cross-border money transfers to over 170 countries.
3. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Analyst Upside Potential: 67.66%
Number of Hedge Fund Holders: 59
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc.
The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has paid $4.00 per share in cash for all Inozyme shares. This acquisition brings a new medicine, INZ-701, into the company’s portfolio. INZ-701 is an enzyme replacement therapy in late-stage development. The drug targets ENPP1 Deficiency, which is a rare and severe genetic disorder that affects blood vessels, soft tissues, and bones.
The process began on May 16, 2025, when both companies announced a merger agreement. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) then started a tender offer on June 2, 2025, and shareholders were offered $4.00 per share. The offer ended on June 30, 2025.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is an international biotechnology company focused on developing and commercializing innovative therapies for rare genetic disorders.
2. Novo Nordisk A/S (NYSE:NVO)
Analyst Upside Potential: 40.42%
Number of Hedge Fund Holders: 60
Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.
The update is based on the new data from the STRIDE trial, which studied people with type 2 diabetes and peripheral artery disease (PAD). The STRIDE trial showed that once-weekly semaglutide improved how far people with PAD and type 2 diabetes could walk. It also improved symptoms and quality of life compared to a placebo.
Novo Nordisk A/S (NYSE:NVO) says that, if approved by the European Commission, Ozempic will be the only GLP-1 drug proven to reduce risks of cardiovascular death, heart attack, stroke, major kidney events, and improve walking in people with type 2 diabetes. Management is expecting the label update in about two months.
Novo Nordisk A/S (NYSE:NVO) is an international healthcare company primarily focused on diabetes care and treatment.
1. Centene Corporation (NYSE:CNC)
Analyst Upside Potential: 105.23%
Number of Hedge Fund Holders: 64
Centene Corporation (NYSE:CNC) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 2, Wolfe Research analyst Justin Lake reiterated a Peer Perform rating on Centene Corporation (NYSE:CNC) without disclosing any price target.
The analyst noted that the company withdrew its 2025 earnings guidance, which was driven by significant pressure in Centene Corporation’s (NYSE:CNC) health insurance business. Notably, due to unexpected and elevated cost trends in Medicaid and challenges in the Health Insurance Marketplace risk adjustment transfers.
Wolfe Research lowered its EPS estimates for 2025 and 2026, expecting that the pressure from Medicaid, which is a much larger part of Centene Corporation (NYSE:CNC)’s business, would not be offset by Medicare or SG&A improvements. Due to the uncertainty surrounding 2026, the firm stated it would not be a buyer on the stock’s weakness following the guidance withdrawal.
Centene Corporation (NYSE:CNC) is a healthcare company that provides integrated services to government-sponsored and commercial healthcare programs.
While we acknowledge the potential of CNC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CNC and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
